Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MGMT | P16455 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534214 | 0.82 | S1PR4 (0.56) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL2673898 | 0.80 | NPC1 (0.60) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL14332895 | 0.79 | PIN1 (0.57) | NPC1RAB9AKMT2AMEN1LMNA | |
| SCHEMBL5530823 | 0.78 | KMT2A (0.60) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL27081712 | 0.76 | MAPT (0.41) | NPC1RAB9AMAPTSMN1; SMN2HTT | |
| SCHEMBL30108290 | 0.76 | MAPT (0.41) | NPC1RAB9AMAPTSMN1; SMN2HTT | |
| SCHEMBL10839905 | 0.76 | SMN1; SMN2 (0.52) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL17646826 | 0.75 | NPC1 (0.51) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL17646828 | 0.75 | NPC1 (0.51) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL17646918 | 0.75 | NPC1 (0.51) | NPC1RAB9AKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814888-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | PFIZER INC | 2006-08-03 | — | — | US | disclosed |
| WO-2006051394-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | CHRNA7, CHRNA5, CHRNA10 | NPC1 1162/4885RAB9A 1609/4885KMT2A 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.